News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Large Scale Biology Corporation - Main Headquarter (LSBC) And Icon Genetics AG Announce Successful Completion Of Research Phase Of Product Development Collaboration


10/19/2005 5:12:18 PM

VACAVILLE, Calif., and MUNICH, Germany, Sept. 21 /PRNewswire-FirstCall/ -- Large Scale Biology Corporation and Icon Genetics (ICON) announced today the successful completion of the research phase of their collaborative program to co-develop a biopharmaceutical product for enzyme replacement therapy and the initiation of the commercial phase of the collaboration.

The alliance has focused on the synergistic application of LSBC's and ICON's patented gene expression and biomanufacturing resources with the goal of developing and commercializing a product for enzyme replacement therapy, the manufacture of which by conventional technologies has proven difficult and expensive. Both ICON and LSBC biomanufacture their own and client- and partner-specified therapeutic proteins using non-food/fodder, non-recombinant plants in safe, contained production environments. The goal of the new collaboration is to accelerate product development by pooling the technical strengths of each company's plant-based platform.

"We are very pleased with the rapid success of our program with Icon Genetics in maximizing the productivity of plant-based production of this important pharmaceutical product candidate," said Kevin J. Ryan, President and CEO of LSBC. "We look forward to continuing our joint accelerated development of an important product, whose availability and cost have been hampered by inefficient manufacturing methods."

"We are happy with the progress of this successful product-focused collaboration with LSBC, whose manufacturing capabilities and clinical trial experience complement ICON's technical strengths," said Yuri Gleba, CEO of Icon Genetics. "We are very optimistic about the opportunities for both Companies in the commercial development of this important product."

About Icon Genetics AG

Icon Genetics, a privately held company headquartered in Munich, Germany, is a provider of new plant engineering technologies to address precision, speed, yield, expression control and safety of transgene management in plants. ICON develops new-generation production platforms and product prototypes for pharmaceutical, agricultural, animal health, chemical and biotechnology markets. The Company owns two subsidiaries: Icon Genetics GmbH, Halle, and Icon Genetics Inc., NJ, USA. ICON's research facilities are in Halle (Saale) and Freising-Weihenstephan, Germany, and occupy over 1000 sq. m of space, including over 300 sq. m of greenhouses. ICON has a pipeline of its own and client- and partner-specified molecules under development. For more information about Icon Genetics, visit the Company's website at www.icongenetics.com.

About Large Scale Biology Corporation

Large Scale Biology Corporation is a biotechnology company developing and biomanufacturing biotherapeutics, vaccines and industrial proteins for important life science industry markets. Corporate headquarters, molecular biology and product design laboratories are located in Vacaville, California, and the Company's bioprocess development and commercial-scale biomanufacturing facilities are located in Owensboro, Kentucky. In addition to its class-leading internal capabilities, LSBC relies on a network of industry, government and academic collaborators throughout the US and Europe to achieve rapid, commercially relevant product discovery, optimization, manufacturing and distribution. For more information about Large Scale Biology Corporation, visit the Company's website at www.lsbc.com .

This release contains forward-looking statements about applications of LSBC's technologies and the markets for our products. These forward-looking statements involve risks, uncertainties and situations that may cause actual results to differ materially from those implied by these statements, including our ability to produce adequate quantities of product, the ability of our collaborators to generate demand for products we make for them, the effectiveness of our and our collaborators' technologies to produce specific therapeutic products and/or in a cost-effective manner, any difficulties or delays in obtaining regulatory approval to test and market such products, and the requirement of substantial funding for us to preserve our technology base and product pipeline. We cannot guarantee future results. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this release. For a further list and description of such risks and uncertainties see the reports filed by Large Scale Biology Corporation with the Securities and Exchange Commission, including our reports on Forms 10-K and 10-Q. Except as required by law, we do not undertake to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

NOTE: LSBC(TM) is a trademark of Large Scale Biology Corporation. ICON(TM) and Icon Genetics(TM) are trademarks of Icon Genetics AG.

Contact: Large Scale Biology Corporation Daniel Tuse, Ph.D. Vice President Business Development 707-469-2316 Icon Genetics AG Yuri Gleba, Ph.D. Chief Executive Officer +49-0-345-555-9887

Large Scale Biology Corporation

CONTACT: Daniel Tuse, Ph.D., Vice President of Business Development ofLarge Scale Biology Corporation, +1-707-469-2316; or Yuri Gleba, Ph.D.,Chief Executive Officer of Icon Genetics AG, +49-0-345-555-9887


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES